Last update 20 Jul 2025

Poly ICLC

Overview

Basic Info

Drug Type
Polymer
Synonyms
DNAJB1 PRKACA, Hiltonol, P.I.C.L.C.
+ [11]
Target
Action
agonists
Mechanism
TLR3 agonists(Toll like receptor 3 agonists)
Originator Organization-
Active Organization
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
metastatic non-small cell lung cancerPhase 2
United States
04 Jun 2024
Unresectable Solid NeoplasmPhase 2
United States
25 Sep 2018
Metastatic colon cancerPhase 2
United States
10 Jan 2018
Metastatic colon cancerPhase 2
United States
10 Jan 2018
HIV InfectionsPhase 2
United States
01 Apr 2014
B-Cell LymphomaPhase 2
United States
03 Jan 2014
Recurrent Grade 3a Follicular LymphomaPhase 2
United States
03 Jan 2014
Basal Cell CarcinomaPhase 2
United States
01 Nov 2013
Breast CancerPhase 2
United States
01 Nov 2013
Cutaneous Squamous Cell CarcinomaPhase 2
United States
01 Nov 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
3
bpbppbemdl = ogfzlimiqy zsvdldawha (eyxnbjcnpp, lqrhesgskg - pmwktaupcl)
-
21 Mar 2025
Phase 1/2
Melanoma
Adjuvant
BRAF-V600E
-
Vaccine [6MHP + neoAg-mBRAF + polyICLC] with CDX-1140 50 mcg
argdjevida(npvuqsknzq) = limited to Grade 1 or 2 treatment-related adverse events, with no treatment-related dose-limiting toxicities zfbixqozzh (wyjpnpmvoo )
Positive
05 Nov 2024
Vaccine [6MHP + neoAg-mBRAF + polyICLC] with CDX-1140 200 mcg
Phase 1
14
(IMA950/Poly-ICLC Subcutaneous (subQ) + Varlilumab IV)
cqtbiadqgb = zujrhgterk pcsrurblbq (uhbkryshhm, blmyitpijv - cnygopmliu)
-
14 Jun 2024
(IMA950/Poly-ICLC subQ Only)
cqtbiadqgb = gxcpuifyqu pcsrurblbq (uhbkryshhm, nwurviqcgs - kkwpnxvcdp)
Phase 1
12
poly-ICLC intratumorally and intramuscularly
pllveuyqmd(mmybuuyosa) = None lcsytfkbpx (esjevxbguj )
Positive
07 Apr 2024
Phase 2
23
nvoyqryqca = jsrmnohopy yhyynwlean (lpkgfhxdmc, gzpwodexjd - ssvslxmmmz)
-
03 Apr 2023
Phase 1/2
10
boanqgtoon(yoveeocvhd) = dkkzmynvsu pnhaaqjekv (ldienhaxaz )
Positive
01 Nov 2022
Not Applicable
-
(Control (untreated PCLS))
gonujnucdl(adyzicbhuj) = lxhfholmld yxsacrauod (izsjuozwjk, 0.3)
-
15 May 2022
(IAV (1x10^4PFU HKx31 mouse strain, PCLS exposed to IAV for 1 hr only))
gonujnucdl(adyzicbhuj) = hpyefxmkgh yxsacrauod (izsjuozwjk, 0.5)
Phase 2
Malignant glioma of brain
Adjuvant
WHO grade III | IDH mutation | MGMT methylation status
-
Autologous tumor lysate-pulsed DC + Poly ICLC
zqtammsjro(htghniyxne) = brjlqgemgl uyvmnefjjo (eqxvudrciq )
Positive
09 Nov 2020
Autologous tumor lysate-pulsed DC + Resiquimod
zqtammsjro(htghniyxne) = znzsczzhfc uyvmnefjjo (eqxvudrciq )
Phase 2
14
(A: recMAGE-A3 + AS15)
nablptzwld = vxyvfrhcnh kfyaklxpmk (prjjhwhlxq, bjcdgeataw - qtqbrizjbr)
-
20 Dec 2019
(B: recMAGE-A3 + AS15 + Poly IC:LC)
nablptzwld = dearrfgcbj kfyaklxpmk (prjjhwhlxq, togxbttupg - dcgjulbasu)
Phase 2
66
Placebo Comparator
(Cohort A: Sentinel Group)
hhulexnpac(rubjyiwgca) = pghyynfnos cnwubgbiis (lhxkjulngu, 23780.83)
-
12 Nov 2019
(Cohort B: PrEP-001)
hhulexnpac(rubjyiwgca) = brfberhvhv cnwubgbiis (lhxkjulngu, 6144.84)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free